Avanos Medical, Inc. (AVNS) 股票分析

公司概述

Avanos Medical, Inc. operates as a medical technology company providing specialized device solutions across North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. The firm focuses on digestive health products, including Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal feeding systems, serving a critical niche within the healthcare sector. Operating in the Medical Devices industry under the broader Healthcare sector, the company leverages its product portfolio to address specific patient needs ranging from adult enteral nutrition to neonatal care. With a market capitalization of $655.29M and annual revenue of $701.20M, Avanos maintains a significant operational footprint supported by a workforce of 2287 employees. These valuation and revenue figures indicate that the company holds a substantial position within its specialized market, balancing a mid-cap status with consistent revenue generation despite the challenges inherent in the medical device landscape.

财务健康

The company reported total revenue of $701.20M over the trailing twelve months, yet recorded a net income loss of $-72,900,000 and an EBITDA of $54.40M, revealing a significant gap where high operating costs or non-operating expenses outweigh pre-tax profits. Despite the net income deficit, the generation of $46.01M in free cash flow demonstrates that the company retains positive cash liquidity after capital expenditures, providing essential financial flexibility for operations and potential strategic initiatives. The gross margin stands at 50.5%, indicating efficient production and pricing power for core products, whereas the operating margin of 2.0% and profit margin of -10.4% suggest that selling, general, and administrative expenses, along with other factors, are substantially eroding pre-tax earnings. On the balance sheet, total cash of $89.80M is lower than total debt of $129.10M, creating a net debt position, while a debt-to-equity ratio of 16.59 highlights a highly leveraged capital structure relative to shareholders' equity. However, a current ratio of 2.15 indicates robust short-term liquidity, suggesting the company possesses sufficient current assets to cover its immediate liabilities without distress. Return on Equity is -9.1% and Return on Assets is 0.9%, metrics that reflect the current period's challenges in generating returns for shareholders and utilizing assets efficiently, respectively, which is typical for a company in a net loss position.

估值评估

The valuation metrics present a complex picture, with a P/E Ratio (TTM) listed as N/A due to the negative earnings, contrasted by a Forward P/E of 11.27 which implies the market prices in an expectation of future earnings recovery. The Price to Book ratio of 0.84 suggests the stock trades at a discount to its book value, indicating a market valuation that does not currently reflect a significant premium over the company's net asset value. Alternative valuation multiples such as a Price to Sales of 0.93 and an EV/EBITDA of 12.77 provide context, showing the company trades at less than one dollar of sales per share while maintaining a moderate enterprise value relative to its EBITDA. Regarding price momentum, the 52-Week High is $15.68 and the 52-Week Low is $9.30, placing the current trading price contextually within this established range relative to historical volatility. The Beta of 1.05 indicates that the stock's price volatility is slightly higher than the broader market, meaning it tends to move in tandem with the general market but with a slight amplification of swings.

Growth & Income

Revenue growth year-over-year is 0.7%, while earnings growth is N/A due to the absence of reported net income in the trailing twelve months, implying that top-line expansion is currently not translating into bottom-line profitability. As a non-dividend payer, the company has a Dividend Yield of N/A and a Payout Ratio of 0.0%, indicating that management currently directs capital toward operational needs and debt management rather than distributing income to shareholders. This reinvestment strategy is consistent with a company prioritizing solvency and potential future earnings restoration over immediate shareholder returns via dividends. The overall growth and income profile reflects a mature yet financially pressured asset where revenue stability coexists with a lack of earnings growth and no current income distribution mechanism.